| abstract |
(57) Summary The present invention relates to a selective inhibitor of mammalian osteoclast activity, a method for producing the same and a pharmaceutical composition comprising the same, and a method of treating the selective inhibitor for administration to a human or animal patient. The selective inhibitors have been found to inhibit vacuolar H + -ATPase, eg, vacuolar H + -ATPase in osteoclasts, and are therefore therapeutically useful for physiological disorders involving bone resorption. It is valid. In an embodiment of the present invention, the selective inhibitor comprises an imidazopyridinecarbonitrile compound of general formula (I). Embedded image |